Oncimmune distributor gets approval for 'EarlyCDT-Lung' in Israel
Immunodiagnostics company Oncimmune Holdings announced on Wednesday that its distributor for Israel, Best Medical Opinion, has received regulatory approval for the sale of the ‘EarlyCDT-Lung’ product in Israel.
The AIM-traded firm said that an age standardised basis, Israel's lung cancer mortality rate was 18.2 per 100,000 persons, making it one of the highest rates in the Middle East region.
Lung cancer was responsible for more cancer-related deaths than any other cancer in the country.
“We welcome this latest approval which paves the way for the near-term commencement of commercial sales in the sophisticated healthcare market of Israel,” said chief executive officer Dr Adam Hill.